CTLA-4 Blockade in GM-CSF Vaccinated Patients

GM-CSF 疫苗接种患者中的 CTLA-4 阻断

• 批准号: 6802868
• 负责人: FRANK S HODI
• 金额: $ 36.47万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-22 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6802868
• 关键词: acute myelogenous leukemia; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; gene therapy; human subject; human therapy evaluation; melanoma; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; nonsmall cell lung cancer; ovary neoplasms; patient oriented research

DESCRIPTION (provided by applicant): Despite convincing evidence for a host's ability to mount immune responses to a large number of cancer-associated gene products, most patients with advanced malignancies still succumb to their disease. One means by which a host may fail to adequately mount an effective anti-tumor immune response is ineffective priming of the immune system in tumor antigen presentation. We have investigated a strategy to augment antigen presentation involving vaccination with autologous, irradiated tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). A majority of metastatic lesions resected after vaccination of patients with metastatic melanoma and non-small cell lung cancer showed brisk or focal T lymphocyte and plasma cell infiltrates with tumor necrosis. While significant numbers of patients achieved durable clinical responses to this vaccination strategy, most eventually develop progressive disease. One mechanism that may limit the therapeutic potency of cancer vaccines is the attenuation of T cell function by CTLA-4. In murine models, concurrent administration of CTLA4 antibody blockade with vaccination with irradiated, GM-CSF secreting tumor cells increases the rejection of poorly immunogenic tumors. To gain a preliminary assessment of the biologic activity of CTLA4 blockade in humans, we treated previously vaccinated patients with metastatic melanoma and ovarian carcinoma with the humanized monoclonal antibody MDX-CTLA4. MDX-CTLA4 stimulated extensive tumor necrosis with lymphocyte and granulocyte infiltrates in three metastatic melanoma patients and the reduction or stabilization of CA-125 levels in two metastatic ovarian carcinoma patients previously vaccinated with irradiated, autologous GM-CSF secreting tumor cells. Potential synergies of MDX-CTLA4 and GM-CSF-based vaccines need further exploration. Currently, we are performing phase I trials of GM-CSF based vaccines using lethally irradiated, autologous tumor cells in patients with metastatic melanoma, metastatic non-small call lung cancer, advanced ovarian cancer, and acute myelogenous leukemia (AML)/advanced myelodysplasia. This offers the unique opportunity to further evaluate the safety and efficacy of this combination therapy in a variety of malignancies, as well as explore antigen-specific changes in T cell responses as a function on CTLA-4 blockade.

描述(申请人提供)：尽管有令人信服的证据证明宿主有能力对大量与癌症相关的基因产物产生免疫反应，但大多数晚期恶性肿瘤患者仍然屈从于他们的疾病。宿主可能不能充分地建立有效的抗肿瘤免疫反应的一种方式是在肿瘤抗原呈递时免疫系统的无效启动。我们研究了一种增强抗原呈递的策略，包括接种能够分泌粒细胞-巨噬细胞集落刺激因子(GM-CSF)的自体照射的肿瘤细胞。转移性黑色素瘤和非小细胞肺癌患者接种疫苗后切除的转移灶大多表现为活跃或局灶性T淋巴细胞和浆细胞浸润，并伴有肿瘤坏死。虽然相当数量的患者对这种疫苗接种策略取得了持久的临床反应，但大多数人最终发展为进展性疾病。可能限制癌症疫苗治疗效力的一个机制是CTLA-4对T细胞功能的减弱。在小鼠模型中，同时给予CTLA4抗体阻断和照射的、分泌GM-CSF的肿瘤细胞接种会增加免疫原性低的肿瘤的排斥反应。为了初步评估CTLA4阻断在人类中的生物学活性，我们用人源化的单抗MDX-CTLA4治疗了以前接种过疫苗的转移性黑色素瘤和卵巢癌患者。在3例转移性黑色素瘤患者中，MDX-CTLA4可刺激广泛的肿瘤坏死，淋巴细胞和粒细胞渗入；在2例卵巢转移癌患者中，MDX-CTLA4可使CA-125水平降低或稳定。基于MDX-CTLA4和GM-CSF的疫苗的潜在协同效应需要进一步探索。目前，我们正在对转移性黑色素瘤、转移性非小细胞肺癌、晚期卵巢癌和急性髓系白血病(AML)/晚期骨髓异常增生症患者使用致死照射的自体肿瘤细胞进行基于GM-CSF的疫苗的I期试验。这为进一步评估这种联合疗法在各种恶性肿瘤中的安全性和有效性，以及探索CTLA-4阻断后T细胞反应的抗原特异性变化提供了独特的机会。